Telix Pharmaceuticals (TLX) Non-Current Debt (2023 - 2025)

Telix Pharmaceuticals (TLX) has 3 years of Non-Current Debt data on file, last reported at $391.9 million in Q4 2025.

• Non-Current Debt for Q4 2025 came in at $391.9 million, up 8.6% year-over-year; the trailing twelve-month figure through Dec 2025 was $391.9 million (up 8.6% YoY), and the FY2025 annual result was $391.9 million, up 14.66% from the prior year.
• Non-Current Debt climbed to $391.9 million in Q4 2025 per TLX's latest filing, from $360.9 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $391.9 million in Q4 2025 and troughed at $5.3 million in Q4 2023.
• A 3-year average of $252.7 million and a median of $360.9 million in 2024 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2024 and 2025: Non-Current Debt jumped 6652.77% in 2024, then rose 8.6% in 2025.
• A 3-year view of Non-Current Debt shows it stood at $5.3 million in 2023, then surged by 6652.77% to $360.9 million in 2024, then rose by 8.6% to $391.9 million in 2025.
• Business Quant data shows TLX's Non-Current Debt at $391.9 million in Q4 2025, $360.9 million in Q4 2024, and $5.3 million in Q4 2023.